SURAKSHA vs THYROCARE: Stock Comparison
THYROCARE TECH is the larger company by market capitalisation. SURAKSHA DIAGNOSTIC shows a lower P/E and faster revenue growth, while THYROCARE TECH shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SURAKSHA leads 5; THYROCARE leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Service Provider | Healthcare Service Provider |
Price
| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| Live Price | ₹341.7 | ₹498.25 |
| Day Change | 0.21% | 2.1% |
| Volume | 1.26 L | 2.22 L |
| 52-Week High | ₹384 | ₹1,610 |
| 52-Week Low | ₹224.1 | ₹342.55 |
| Distance from 52W High | -11.02% | -69.05% |
Valuation
| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| Market Cap | ₹1,801 Cr | ₹7,926 Cr |
| P/E Ratio | 43.06x | 54.97x |
| P/B Ratio | 6.52x | 14.32x |
| EPS | ₹2.5 | ₹1 |
| Book Value | ₹46.75 | ₹36.82 |
| Dividend Yield | 0.29% | 1.41% |
Growth
| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| Revenue Growth (TTM YoY) | 31.2% | 19.7% |
| EPS Growth (TTM YoY) | -5.4% | 116.3% |
| Qtr Sales Growth | 0% | 12.83% |
| Qtr Profit Growth | 0% | -70.35% |
Profitability & Leverage
| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| ROE | 13.64% | 26.54% |
| ROCE | 15.19% | 28.32% |
| Net Margin | 10.37% | 19.67% |
| Operating Margin | 19.81% | 27.46% |
| Debt to Equity | 0.01x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SURAKSHA | THYROCARE |
|---|---|---|
| Promoter Holding | 49.1% | 51.02%▼ 9.9 pp |
| FII Holding | 13.97%▲ 0.5 pp | 9.37%▲ 3.93 pp |
| DII Holding | 21.56%▼ 1.67 pp | 25.92%▲ 5 pp |
| Public Holding | 15.37%▲ 1.16 pp | 13.7%▲ 0.98 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SURAKSHA DIAGNOSTIC and THYROCARE TECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.

